Placebo + Daxdilimab
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Discoid Lupus Erythematosus
Conditions
Discoid Lupus Erythematosus
Trial Timeline
Dec 29, 2022 → May 8, 2025
NCT ID
NCT05591222About Placebo + Daxdilimab
Placebo + Daxdilimab is a phase 2 stage product being developed by Amgen for Discoid Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT05591222. Target conditions include Discoid Lupus Erythematosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05591222 | Phase 2 | Terminated |
Competing Products
7 competing products in Discoid Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab | Novartis | Phase 2 | 52 |
| Tofacitinib citrate | Pfizer | Phase 1 | 32 |
| Etanercept | Pfizer | Phase 2 | 51 |
| Deucravacitinib + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| Belimumab 1 mg/kg + Belimumab 10 mg/kg | GSK plc | Pre-clinical | 22 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| R932333 + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |